Menu
Back to User profile » Dr Rafael Rosell
Papers published by Dr Rafael Rosell:
Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
Karachaliou N, Fernandez Bruno M, Bracht JWP, Rosell R
OncoTargets and Therapy 2019, 12:4567-4575
Published Date: 13 June 2019
Response to crizotinib in a non-small-cell lung cancer patient harboring an EML4-ALK fusion with an atypical LTBP1 insertion
Aguado C, Gil MDLL, Yeste Z, Giménez-Capitán A, Teixidó C, Karachaliou N, Viteri S, Rosell R, Molina-Vila MA
OncoTargets and Therapy 2018, 11:1117-1120
Published Date: 1 March 2018
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy
Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R
Lung Cancer: Targets and Therapy 2017, 8:109-125
Published Date: 18 August 2017
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy
Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G
Drug Design, Development and Therapy 2017, 11:2047-2063
Published Date: 5 July 2017
Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
Passaro A, Lazzari C, Karachaliou N, Spitaleri G, Pochesci A, Catania C, Rosell R, de Marinis F
OncoTargets and Therapy 2016, 9:6361-6376
Published Date: 17 October 2016
Targeting PD-1/PD-L1 in lung cancer: current perspectives
González-Cao M, Karachaliou N, Viteri S, Morales-Espinosa D, Teixidó C, Sánchez Ruiz J, Molina-Vila MÁ, Santarpia M, Rosell R
Lung Cancer: Targets and Therapy 2015, 6:55-70
Published Date: 31 July 2015
Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
Karachaliou N, Rosell R
Lung Cancer: Targets and Therapy 2014, 5:73-79
Published Date: 13 November 2014